Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have signed an informed consent form agreeing to take part in the trial.
- People aged 18 to 75 years old.
- People who are largely able to carry out daily activities with little or no limitation (a measure of general health and physical functioning, confirm with trial site).
- People with a life expectancy of at least 3 months.
- People who have been confirmed through lab testing of tissue or cell samples to have locally advanced or spreading/returning non-small cell lung cancer (NSCLC) that is not suitable for curative surgery or full-course combined chemotherapy and radiation treatment.
- People in Cohort 1: whose cancer has come back or worsened after one prior treatment for advanced disease, and whose cancer has a specific protein or gene change called HER2 amplification or overexpression.
- People in Cohort 2: who have not yet received any systemic treatment for their cancer, and whose cancer has a HER2 amplification or overexpression.
- People who have at least one tumour that can be measured using standard imaging criteria (RECIST 1.1).
- People whose liver, kidneys, and bone marrow are functioning well enough to tolerate treatment (confirm with trial site).
- People who are willing and able to use effective contraception during the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a history of a serious lung condition called interstitial lung disease (ILD), or inflammation of the lungs that required steroid treatment, or currently active non-infectious lung inflammation.
- People who have had a blood clot in an artery or vein within the past 6 months.
- People with significant heart or blood vessel disease.
- People with an active autoimmune disease that currently requires ongoing medical treatment.
- People who have used medications that suppress the immune system within the 2 weeks before joining the trial.
- People with fluid build-up around the lungs, heart, or abdomen that is causing symptoms and requires drainage.
- People with brain or spinal cord metastases (cancer spread to the central nervous system) that are causing symptoms, are growing, or have spread widely.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Li Zhang, Professor, Sun Yat-sen University
Phone: +86-20-87343289
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.